Portage Biotech Inc (PRTG) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Portage Biotech Inc. reported a significant reduction in net loss to $1.4 million for the fiscal quarter ending September 30, 2024, compared to the previous year’s $5.2 million. This improvement is attributed to decreased R&D and operating expenses, as the company pauses its ADPORT-601 trial due to financial constraints. Portage is exploring strategic alternatives, including partnerships or mergers, to enhance shareholder value.
For further insights into PRTG stock, check out TipRanks’ Stock Analysis page.
